These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 16227109)

  • 1. Type III hyperlipoproteinemia with xanthomas and multiple myeloma.
    Burnside NJ; Alberta L; Robinson-Bostom L; Bostom A
    J Am Acad Dermatol; 2005 Nov; 53(5 Suppl 1):S281-4. PubMed ID: 16227109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unusual xanthomas in a young patient with heterozygous familial hypercholesterolemia and type III hyperlipoproteinemia.
    Feussner G; Dobmeyer J; Nissen H; Hansen TS
    Am J Med Genet; 1996 Oct; 65(2):149-54. PubMed ID: 8911609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hyperlipoproteinemia type III with apolipoprotein E phenotype 2/2].
    Engst R
    Hautarzt; 1985 Nov; 36(11):629-34. PubMed ID: 4077508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular mechanisms of type III hyperlipoproteinemia: The contribution of the carboxy-terminal domain of ApoE can account for the dyslipidemia that is associated with the E2/E2 phenotype.
    Kypreos KE; Li X; van Dijk KW; Havekes LM; Zannis VI
    Biochemistry; 2003 Aug; 42(33):9841-53. PubMed ID: 12924933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apolipoprotein E phenotype frequency in type II diabetic patients with different forms of hyperlipoproteinemia.
    Parhofer KG; Richter WO; Schwandt P
    Horm Metab Res; 1990 Nov; 22(11):589-94. PubMed ID: 2272605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Severe type III hyperlipoproteinemia with unusual lipoprotein phenotype in an adolescent patient].
    Ziemer A; Göring HD
    Hautarzt; 1993 Aug; 44(8):538-44. PubMed ID: 8376110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetics of type III hyperlipoproteinemia.
    Feussner G; Piesch S; Dobmeyer J; Fischer C
    Genet Epidemiol; 1997; 14(3):283-97. PubMed ID: 9181357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tuberous xanthomas associated with olanzapine therapy and hypertriglyceridemia in the setting of a rare apolipoprotein E mutation.
    Sinnott BP; Mazzone T
    Endocr Pract; 2006; 12(2):183-7. PubMed ID: 16690468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein E2-Christchurch (136 Arg----Ser). New variant of human apolipoprotein E in a patient with type III hyperlipoproteinemia.
    Wardell MR; Brennan SO; Janus ED; Fraser R; Carrell RW
    J Clin Invest; 1987 Aug; 80(2):483-90. PubMed ID: 3038959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [From gene to disease; apolipoprotein E2 and familial dysbetalipoproteinemia].
    Smelt AH
    Ned Tijdschr Geneeskd; 2003 Jan; 147(4):157-9. PubMed ID: 12635547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Apolipoprotein E phenotyping--useful in the study of hyperlipoproteinemia type III].
    Hagve TA; Furuset T; Christophersen B; Ose L
    Tidsskr Nor Laegeforen; 1993 Mar; 113(7):853-6. PubMed ID: 8480294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apolipoprotein E3-Leiden. A new variant of human apolipoprotein E associated with familial type III hyperlipoproteinemia.
    Havekes L; de Wit E; Leuven JG; Klasen E; Utermann G; Weber W; Beisiegel U
    Hum Genet; 1986 Jun; 73(2):157-63. PubMed ID: 3721502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoprotein E (role in lipoprotein metabolism and pathophysiology of hyperlipoproteinemia type III).
    Utermann G
    Ric Clin Lab; 1982; 12(1):23-30. PubMed ID: 6283616
    [No Abstract]   [Full Text] [Related]  

  • 14. Non-HDL-cholesterol/apolipoprotein B ratio: a useful distinguishing feature in the screening for type III hyperlipoproteinemia.
    Murase T; Okubo M; Takeuchi I
    J Clin Lipidol; 2010; 4(2):99-104. PubMed ID: 21122636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Type III hyperlipoproteinemia: recent insights into the genetic defect of familial dysbetalipoproteinemia.
    Mahley RW; Angelin B
    Adv Intern Med; 1984; 29():385-411. PubMed ID: 6369930
    [No Abstract]   [Full Text] [Related]  

  • 16. The composition, structural properties and binding of very-low-density and low-density lipoproteins to the LDL receptor in normo- and hypertriglyceridemia: relation to the apolipoprotein E phenotype.
    Dergunov AD; Novoselov AV; Visvikis S; Siest G; Yakushkin VV; Tsibulsky V
    Biol Chem; 2005 May; 386(5):441-52. PubMed ID: 15927888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dysbetalipoproteinaemia--clinical and pathophysiological features.
    Blom DJ; Byrnes P; Jones S; Marais AD
    S Afr Med J; 2002 Nov; 92(11):892-7. PubMed ID: 12506591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type III dyslipoproteinemia in patients heterozygous for familial hypercholesterolemia and apolipoprotein E2. Evidence for a gene-gene interaction.
    Hopkins PN; Wu LL; Schumacher MC; Emi M; Hegele RM; Hunt SC; Lalouel JM; Williams RR
    Arterioscler Thromb; 1991; 11(5):1137-46. PubMed ID: 1680391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apolipoprotein E2 (Arg-136-->Cys), a variant of apolipoprotein E associated with late-onset dominance of type III hyperlipoproteinaemia.
    Feussner G; Albanese M; Mann WA; Valencia A; Schuster H
    Eur J Clin Invest; 1996 Jan; 26(1):13-23. PubMed ID: 8682150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apolipoprotein EBethesda: a new variant of apolipoprotein E associated with type III hyperlipoproteinemia.
    Gregg RE; Ghiselli G; Brewer HB
    J Clin Endocrinol Metab; 1983 Nov; 57(5):969-74. PubMed ID: 6578216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.